Almirall gets positive test results on COPD drug.
M2 EUROPHARMA-(C)1999-2010 M2 COMMUNICATIONS
12 January 2010 - Spain-based pharmaceutical company Almirall (MCE: ALM) and its US partner Forest Laboratories got positive preliminary results in a phase three study with their aclidinium drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD), Almirall said yesterday.
The test lasted for three months and consisted of comparison between the administration of aclidinium twice a day and placebo.
According to the World Health Organisation (WHO), some 300 million people worldwide suffer from asthma while 210 million have COPD.
COPD is also known as chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD)
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 13, 2010|
|Previous Article:||Nutri Pharma unveils offer for vaccine developer.|
|Next Article:||GSK to advance development of ChemoCentryx's Traficet-EN.|